The interaction between the chemokine, CXCL12 and its receptor, CXCR4 is known to be involved in several intractable disease processes, including HIV infection, cancer cell metastasis, leukemia cell progression and rheumatoid arthritis. It is conjectured that this interaction may be an important therapeutic target in all of these diseases, and various CXCR4 antagonists have been proposed as potential drugs. This article describes the development in our laboratory of a number of specific CXCR4 antagonists.
Keywords: Cancer metastasis, Chemokine receptor, HIV infection, Leukemia cell progression, Low molecular weight CXCR4 antagonist, Rheumatoid arthritis
open access plus
Rights & PermissionsPrintExport